Clinical Trial Update: Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) [Phase 2]

View source ↗

Summary

A Phase 2 study of Sapablursen in beta-thalassemia intermedia was terminated and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia Intermedia

Drugs mentioned

• Sapablursen (sapablursen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Beta Thalassemia Intermedia | Phase 2 | Status: TERMINATED | Results posted: 2025-02-18